ArticleInfection and drug resistance2025
Detection of
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Parasite based biotherapy for cancer therapeutic strategies and preclinical applications.Discover oncology · 2026Review
- A Systematic Review and Meta-Analysis of Diagnostic Test Accuracy for Human Toxoplasmosis: Performance, Populations, and Validation Gaps.Medical devices (Auckland, N.Z.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Breast cancer is the most prevalent malignancy among women. In recent years, it has been suggested that various pathogens such as Methods: The study included 136 paraffin-embedded biopsy samples with w confirmed malignant breast tumor diagnosis and 50 breast tissue samples diagnosed as benign breast lesions, serving as controls. The presence of Results: The most common histopathological types of malignant breast carcinoma were invasive carcinoma (n=82; 60.3%), invasive lobular carcinoma (n=26; 19.1%), invasive ductal carcinoma (n=8; 5.9%), and mixed invasive carcinoma (n=8; 5.9%). According to the Modified Bloom-Richardson classification, 55.15% of malignant breast tumor samples were grade 2, 32.4% were grade 3, and 12.5% were grade 1. Real-time PCR analysis did not detect Conclusion: Our findings do not support a role of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.